Review



human kinome crispr knockout library preparation  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc human kinome crispr knockout library preparation
    Human Kinome Crispr Knockout Library Preparation, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 51 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kinome crispr knockout library preparation/product/Addgene inc
    Average 93 stars, based on 51 article reviews
    human kinome crispr knockout library preparation - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    93
    Addgene inc human kinome crispr knockout library preparation
    Human Kinome Crispr Knockout Library Preparation, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kinome crispr knockout library preparation/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    human kinome crispr knockout library preparation - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    96
    Addgene inc human kinome crispr knockout library addgene
    Human Kinome Crispr Knockout Library Addgene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kinome crispr knockout library addgene/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    human kinome crispr knockout library addgene - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    93
    Addgene inc human kinome crispr pooled library
    Human Kinome Crispr Pooled Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kinome crispr pooled library/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    human kinome crispr pooled library - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    96
    Addgene inc human kinome crispr knockout library brunello
    <t>CRISPR</t> screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout <t>kinome</t> library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).
    Human Kinome Crispr Knockout Library Brunello, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kinome crispr knockout library brunello/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    human kinome crispr knockout library brunello - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    93
    Addgene inc human kinome
    <t>CRISPR</t> screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout <t>kinome</t> library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).
    Human Kinome, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kinome/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    human kinome - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Addgene inc mdia1
    <t>CRISPR</t> screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout <t>kinome</t> library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).
    Mdia1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mdia1/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    mdia1 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    CRISPR screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout kinome library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).

    Journal: Advanced Science

    Article Title: Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies

    doi: 10.1002/advs.202512074

    Figure Lengend Snippet: CRISPR screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout kinome library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).

    Article Snippet: Human kinome CRISPR knockout library (Brunello) was obtained from Addgene (#73179) and was packaged into lentivirus.

    Techniques: CRISPR, Mutagenesis, Knock-Out, Western Blot, Two Tailed Test